FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian Cancer

The priority review was based on results from the phase III PAOLA-1 trial comparing the addition of olaparib to bevacizumab vs the standard-of-care alone.

Source: CancerNetwork - January 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news